Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.
about
P1343
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesisActivity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancerIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesDistinct modulated pupil function system for real-time imaging of living cellsIndividual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumorsTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Stepwise movements in vesicle transport of HER2 by motor proteins in living cellsDynamics of different-sized solid-state nanocrystals as tracers for a drug-delivery system in the interstitium of a human tumor xenograftIn vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots.Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging.A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.RF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.Synthesis and Characterization of Anti-HER2 Antibody Conjugated CdSe/CdZnS Quantum Dots for Fluorescence Imaging of Breast Cancer Cells.Inflammatory breast cancer (IBC): clues for targeted therapiesEpidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancerHigh-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer CellsAnti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer ProgressionAdditive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cellsThe effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cellsAnti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains on their surfaceDrug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseAntigen-responsive molecular sensor enables real-time tumor-specific imaging.Stable and Potent Selenomab-Drug Conjugates.BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.Recombinant protein (EGFP-Protein G)-coated PbS quantum dots for in vitro and in vivo dual fluorescence (visible and second-NIR) imaging of breast tumors.Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.Aqueous synthesis of glutathione-coated PbS quantum dots with tunable emission for non-invasive fluorescence imaging in the second near-infrared biological window (1000-1400 nm).Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.Killed Bacillus subtilis spores expressing streptavidin: a novel carrier of drugs to target cancer cells.Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
P2860
Q24598092-98841C4A-8466-490F-A6B8-8C1166889E5FQ24615262-8F27DA99-3145-4DF6-97F2-F1EA4E7AC2B9Q27014174-F061A94B-927E-45D2-8E90-FEFD893B75D5Q27321367-1DB589C8-1BCE-4D3F-A279-B7C5FCA290BEQ28302352-694DCC6A-5B1D-4136-84C2-FCFD3523C53AQ28550300-91B5AF04-5088-4AE4-8E4C-C27F55108786Q30412086-C97F093B-2CDB-4390-B116-F17C9B9DACD5Q30479459-0A2CE545-4E8D-4688-B307-1C0821D0E6A5Q30490487-66CABC32-0ADB-4C04-960E-74BBC53A877AQ30492792-27EA180B-BFA7-4320-A780-A2AC7BAE763CQ30665854-D65F69A5-0C40-449D-80C0-E8F7194FDAA0Q31110832-B7E39B8C-4A87-4D05-B129-5B086B6E4E89Q33658544-B4DB01D5-85A1-4D1C-A782-259DA0E1804FQ33722847-FDC8A013-B432-474C-9F96-C90082E5B10CQ33780009-37114538-E0A3-4F34-9254-63E141FD649AQ34145580-B9D6AD57-052C-4F34-B2F2-266C2CACC66FQ34754098-277E49B6-CD4E-4AC5-BC3A-63E7CB9A2878Q35007782-CACD182A-E138-48EF-962C-AEB8F89DEE2BQ35024073-3CB3FD37-181A-4DDF-BFA1-44DEE0094E4BQ35274741-49C9A72F-68EE-4264-9D48-71DFB747C3CFQ35710589-A02B0F53-43A0-40F3-964E-DF9B8D9690B6Q36620845-7EBB75ED-AB15-4CE5-AE02-026E62E99D20Q36657315-E8D56D0C-EE09-496D-A5FC-3B31FDA66150Q36673777-492D12EC-4EB0-4BF8-AAD1-01059636C8F5Q36725203-0E57DA8B-A4E1-40F1-AECA-C3EAB0561AF3Q37138981-AEEBCBC5-85D9-4977-9290-A1C5FA76B1FFQ37289437-7B4E133A-7BE0-4016-B53B-FDF0CEECDFD3Q37403163-B538ADDA-84D3-4B36-80A9-2F5868D1B909Q37722926-A73F5388-0C40-4315-835D-D9EE27BD65DBQ37738232-493E42EE-DAE5-45B0-80BA-0466ECA65FFDQ38432502-A7AACC6F-9CE3-44A1-9FF8-98919EB096FFQ38739375-9A72D751-DB9E-4D0A-A511-D11E1A64122FQ38922562-A81E41D9-B384-4CA4-B1D1-783F03A58C52Q38924096-092CEA45-114B-4837-B489-D79E5C3DC879Q39040565-FBDF2A4F-FF03-4E46-A320-859A7D564C24Q39123848-6CCB3528-F1B2-4F1D-8F46-0B722551C7E3Q39141313-1F840A04-1DD3-4B62-A03A-1C7662E43787Q39182344-D2985CC1-BD53-40F9-B603-97FF790C9E38Q39372888-D3669B1C-F861-4BBD-9A26-50002EB512B9Q39664583-7B374514-B2BA-421F-A1D6-20FC5F7E3CCF
P2860
Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Isolation and characterization ...... y receptors and interleukin-6.
@ast
Isolation and characterization ...... y receptors and interleukin-6.
@en
type
label
Isolation and characterization ...... y receptors and interleukin-6.
@ast
Isolation and characterization ...... y receptors and interleukin-6.
@en
prefLabel
Isolation and characterization ...... y receptors and interleukin-6.
@ast
Isolation and characterization ...... y receptors and interleukin-6.
@en
P2093
P2860
P356
P1476
Isolation and characterization ...... y receptors and interleukin-6.
@en
P2093
Kurebayashi J
Kurosumi M
Mochizuki M
Nakamura H
Yamamoto S
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690114
P407
P4510
P577
1999-02-01T00:00:00Z
P5875
P6179
1019124658